{"id":"NCT01349907","sponsor":"Organon and Co","briefTitle":"Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)","officialTitle":"A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-16","primaryCompletion":"2014-09-05","completion":"2014-09-05","firstPosted":"2011-05-09","resultsPosted":"2015-03-09","lastUpdate":"2024-05-22"},"enrollment":322,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Asenapine","otherNames":["SCH 900274, ORG 5222"]},{"type":"DRUG","name":"Rescue medication","otherNames":[]}],"arms":[{"label":"Asenapine/Asenapine","type":"EXPERIMENTAL"},{"label":"Placebo/Asenapine","type":"EXPERIMENTAL"}],"summary":"This study will investigate the safety and tolerability of a flexible dosing regimen of asenapine for the long-term treatment of manic or mixed episodes associated with bipolar disorder I in children and adolescents who completed study P06107.","primaryOutcome":{"measure":"Number of Participants Who Experienced Clinical or Laboratory Adverse Events","timeFrame":"Baseline (Day 1) to 30 days after the last dose of study drug (up to approximately 54 weeks)","effectByArm":[{"arm":"Asenapine/Asenapine","deltaMin":197,"sd":null},{"arm":"Placebo/Asenapine","deltaMin":74,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26598478","27461426"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":241},"commonTop":["Somnolence","Weight increased","Sedation","Headache","Nausea"]}}